AbbVie | ABBV - Interest Expense On Debt

Stock Price
231.50
Daily Change
4.00 1.76%
Monthly
4.33%
Yearly
20.03%
Q1 Forecast
216.57

AbbVie reported $740M in Interest Expense on Debt for its fiscal quarter ending in June of 2025.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Abbott USD 42M 2M Dec/2025
ALKERMES USD 4.65M 1.35M Dec/2024
Amgen USD 653M 32M Dec/2025
AstraZeneca USD 484M 181M Dec/2025
Biogen USD 72.6M 12.6M Jun/2025
BioMarin Pharmaceutical USD 2.58M 100K Sep/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Coherus Biosciences USD 2.15M 3.2M Mar/2025
Eisai JPY 1.43B 12M Dec/2025
Eli Lilly USD 114.7M 134.3M Sep/2025
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
J&J USD 18M 290M Sep/2025
Medtronic USD 181M 5M Sep/2025
Merck USD 412M 85M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Pacira USD 4.28M 456K Sep/2025
Perrigo USD 10.08B 10.04B Sep/2025
Pfizer USD 711M 59M Dec/2025
Regeneron Pharmaceuticals USD 12.2M 7.1M Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sanofi EUR -25M 252M Dec/2025
UCB EUR 78M 30M Jun/2025
Ultragenyx Pharmaceutical USD 19M 4.85M Dec/2025
United Therapeutics USD 3M 4.3M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025
Zoetis USD 57M 1000K Dec/2025